Fujifilm Irvine Scientific Builds Bioprocessing Innovation and Collaboration Center in China

Fujifilm Irvine Scientific, which develops and manufactures serum-free and chemically-defined cell culture media for bioproduction and cell therapy manufacturing, announced in a Dec. 1, 2021, press release that it is building an Innovation and Collaboration Center in Suzhou New District, China to help local customers design upstream cell culture processes. The company noted in the press release that the market for cell culture media is expanding due to rapid growth in China’s biopharmaceutical, vaccine, and cell and gene therapy markets.

The new center will incorporate advanced cell culture automation and analysis into process and media development to optimize cell culture media and associated workflows for upstream cell culture processes. This optimization will help achieve the quantity and product quality attributes necessary to support commercial production of new drugs. Construction has begun and is planned for completion by March 2022.

“We are increasing the number of sales and technical support staff throughout China to meet the development needs and support the antibody pharmaceutical industry in the growing Chinese market,” said Yutaka Yamaguchi, chairman and CEO, Fujifilm Irvine Scientific, general manager Fujifilm Life Sciences Business Division, in the press release.

In November 2021, the company had announced that it was expanding its R&D Center of Excellence at its headquarters in California to support discovery research and specialty media, technologies, and custom media services.

Source: Fujifilm